DBV Technologies Files 8-K on Board and Officer Changes
Ticker: DBVTF · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1613780
| Field | Detail |
|---|---|
| Company | Dbv Technologies S.A. (DBVTF) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
DBV Tech 8-K: Board and exec changes filed 9/18. Watch for strategic shifts.
AI Summary
DBV Technologies S.A. filed an 8-K on September 18, 2025, reporting on the departure of directors, election of directors, appointment of officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and officer composition can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- DBV Technologies S.A. (company) — Registrant
- September 18, 2025 (date) — Date of Report
FAQ
What specific director departures were reported?
The filing indicates the departure of directors, but does not name them in the provided text.
Were any new directors or officers appointed?
Yes, the filing explicitly mentions the election of directors and the appointment of certain officers.
What is the nature of the compensatory arrangements disclosed?
The filing states that information regarding compensatory arrangements of certain officers is included, but specific details are not in the provided text.
Does this filing include any financial statements?
Yes, the filing lists 'Financial Statements and Exhibits' as an item information.
What is the primary business of DBV Technologies S.A. according to the filing?
DBV Technologies S.A. is categorized under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-18 16:42:48
Filing Documents
- d934130d8k.htm (8-K) — 29KB
- d934130dex991.htm (EX-99.1) — 8KB
- g934130dsp1.jpg (GRAPHIC) — 31KB
- g934130dsp2.jpg (GRAPHIC) — 21KB
- 0001193125-25-207507.txt ( ) — 260KB
- dbvt-20250918.xsd (EX-101.SCH) — 3KB
- dbvt-20250918_def.xml (EX-101.DEF) — 13KB
- dbvt-20250918_lab.xml (EX-101.LAB) — 22KB
- dbvt-20250918_pre.xml (EX-101.PRE) — 14KB
- d934130d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated September 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. DBV Technologies S.A. Date: September 18, 2025 By: /s/ Virginie Boucinha Name: Virginie Boucinha Title: Chief Financial Officer